Skip to main content
. 2019 Nov 13;4(6):e000590. doi: 10.1136/esmoopen-2019-000590

Table 1.

Patients and study components

Study patients Tumour tissues
BRAF V600E mutant BRAF V600E mutation negative or unanalysable
Blood sample
(ctDNA analysis)
BRAFV600E mutant Primary analysis part Liquid biopsy part
BRAFV600E mutation negative or not evaluated Primary analysis part Not enrolled in the study

ctDNA, circulating tumor DNA.